| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 148, 549-558, Copyright © 1996 by American Society for Investigative Pathology
REGULAR ARTICLES |
SS Bacus, D Chin, Y Yarden, CR Zelnick and DF Stern
Advanced Cellular Diagnostics, Inc., Elmhurst, Illinois, USA.
The neu/erbB-2/HER-2 proto-oncogene is amplified and/or overexpressed in up to 30% of mammary carcinomas and has been variably correlated with poor prognosis. The signaling activity of the encoded receptor tyrosine kinase is regulated by interactions with other type 1 receptors and their ligands. We have used a novel approach, phosphorylation-sensitive anti-Neu antibodies, to quantify signaling by Neu and epidermal growth factor receptor in a panel of frozen sections of mammary carcinoma specimens. We also determined the relationship of Neu, phosphorylated Neu (and epidermal growth factor receptor), and phosphotyrosine to the expression of Neu-related receptors (epidermal growth factor receptor, HER-3, and HER-4) and to prognostic factors (estrogen and progesterone receptor). We found that tyrosine phosphorylation of Neu (and hence signaling activity) is highly variable among mammary carcinomas. Neu and HER-4 were associated with divergent correlates, suggesting that they have profoundly different biological activities. These results have implications for etiology of mammary carcinoma for clinical evaluation of mammary carcinoma patients, and for development of Neu-targeted therapeutic strategies.
This article has been cited by other articles:
 |
|
 |
|
  M. Rokavec, C. Justenhoven, W. Schroth, M. A. Istrate, S. Haas, H.-P. Fischer, C. Vollmert, T. Illig, U. Hamann, Y.-D. Ko, et al. A Novel Polymorphism in the Promoter Region of ERBB4 Is Associated with Breast and Colorectal Cancer Risk Clin. Cancer Res., December 15, 2007; 13(24): 7506 - 7514. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. I. Aqeilan, V. Donati, E. Gaudio, M. S. Nicoloso, M. Sundvall, A. Korhonen, J. Lundin, J. Isola, M. Sudol, H. Joensuu, et al. Association of Wwox with ErbB4 in Breast Cancer Cancer Res., October 1, 2007; 67(19): 9330 - 9336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. E. Strunk, C. Husted, L. C. Miraglia, M. Sandahl, W. A. Rearick, D. M. Hunter, H. S. Earp III, and R. S. Muraoka-Cook HER4 D-Box Sequences Regulate Mitotic Progression and Degradation of the Nuclear HER4 Cleavage Product s80HER4 Cancer Res., July 15, 2007; 67(14): 6582 - 6590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhu, L. L. Sullivan, S. S. Nair, C. C. Williams, A. K. Pandey, L. Marrero, R. K. Vadlamudi, and F. E. Jones Coregulation of Estrogen Receptor by ERBB4/HER4 Establishes a Growth-Promoting Autocrine Signal in Breast Tumor Cells Cancer Res., August 15, 2006; 66(16): 7991 - 7998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. T. Junttila, M. Sundvall, M. Lundin, J. Lundin, M. Tanner, P. Harkonen, H. Joensuu, J. Isola, and K. Elenius Cleavable ErbB4 Isoform in Estrogen Receptor-Regulated Growth of Breast Cancer Cells Cancer Res., February 15, 2005; 65(4): 1384 - 1393. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Zinser and J. Welsh Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice Carcinogenesis, December 1, 2004; 25(12): 2361 - 2372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Mandell Phosphorylation State-Specific Antibodies: Applications in Investigative and Diagnostic Pathology Am. J. Pathol., November 1, 2003; 163(5): 1687 - 1698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Atalay, F. Cardoso, A. Awada, and M. J. Piccart Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer Ann. Onc., September 1, 2003; 14(9): 1346 - 1363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Ariazi, G. M. Clark, and J. E. Mertz Estrogen-related Receptor {alpha} and Estrogen-related Receptor {gamma} Associate with Unfavorable and Favorable Biomarkers, Respectively, in Human Breast Cancer Cancer Res., November 15, 2002; 62(22): 6510 - 6518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Penington, I. Bryant, and D. J. Riese II Constitutively Active ErbB4 and ErbB2 Mutants Exhibit Distinct Biological Activities Cell Growth Differ., June 1, 2002; 13(6): 247 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. B. Motoyama, N. E. Hynes, and H. A. Lane The Efficacy of ErbB Receptor-targeted Anticancer Therapeutics Is Influenced by the Availability of Epidermal Growth Factor-related Peptides Cancer Res., June 1, 2002; 62(11): 3151 - 3158. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Suo, H. Yang, Q. Mei, E. Skovlund, J. Cui, and J. M. Nesland Type 1 Protein Tyrosine Kinases in Chinese Breast Carcinomas: A Clinicopathologic Study International Journal of Surgical Pathology, July 1, 2001; 9(3): 177 - 187. [Abstract] [PDF]
|
|
|
|
 |
|
 F. E. Jones, T. Welte, X.-Y. Fu, and D. F. Stern ErbB4 Signaling in the Mammary Gland Is Required for Lobuloalveolar Development and Stat5 Activation during Lactation J. Cell Biol., October 4, 1999; 147(1): 77 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. K. Tang, X.-Z. W. Concepcion, M. Milan, X. Gong, E. Montgomery, and M. E. Lippman Ribozyme-mediated Down-Regulation of ErbB-4 in Estrogen Receptor-positive Breast Cancer Cells Inhibits Proliferation Both in Vitro and in Vivo Cancer Res., October 1, 1999; 59(20): 5315 - 5322. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Gioeli, J. W. Mandell, G. R. Petroni, H. F. Frierson Jr., and M. J. Weber Activation of Mitogen-Activated Protein Kinase Associated with Prostate Cancer Progression Cancer Res., January 1, 1999; 59(2): 279 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Riese II, T. Komurasaki, G. D. Plowman, and D. F. Stern Activation of ErbB4 by the Bifunctional Epidermal Growth Factor Family Hormone Epiregulin Is Regulated by ErbB2 J. Biol. Chem., May 1, 1998; 273(18): 11288 - 11294. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
